Drug Approval | January 17, 2025
FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The company has received the GMP Certification after successful closure of the inspection
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Subscribe To Our Newsletter & Stay Updated
